Geron Corp is a US-based pharmaceutical company specializing in cancer treatment research. With a focus on environment, sustainability, and governance (ESG), the company has a medium risk rating score of 27.9. Geron's drug Imelstat is currently in development for myelodysplastic syndromes and myelofibrosis. Revenue is generated through collaborations, milestones, royalties, and licensing. Geron operates in the oncology segment.